When the risk to develop dementia is assessed, either no effects [347] or reduced odds ratio to develop dementia has been reported in diabetes patients on GLP1 analogs, showing that as the daily defined dose increases, the risk to develop dementia is reduced [320]. This evidence concerns the gene GLP1R and dementia.